Virginia Tech at AMP 2026
Nov 10–14, 2026 Seattle, WA ~2k attendees Website
Virginia Tech brings 2 presentations to AMP 2026 in Seattle. Its programme centres on measurable residual disease testing across blood cancers and solid tumours. The sessions cover personalised tumour-informed droplet digital PCR assays and what it takes to make residual disease testing in acute myeloid leukaemia routine practice.
| Organization | AMP 2026 Attendance |
|---|---|
Virginia Tech Blacksburg, VA | |
Public research university in Blacksburg, Virginia, with colleges of veterinary medicine, science and engineering and biomedical research institutes. | Workshop Wed, Nov 11 8:00am–8:50am MRD Detection & Monitoring in Solid Tumors and Heme Malignancies Using Personalized Tumor Informed Droplet Digital PCR (ddPCR) Assays in Research Settings Tumour-informed droplet digital PCR assays for tracking residual disease in both blood cancers and solid tumours. Talk Sat, Nov 14 2:30pm–2:45pm Measurable Residual Disease Testing in Acute Myeloid Leukemia: Moving From Theory to Practice Measurable residual disease testing in acute myeloid leukemia: consensus guidance, where assays fall short, and how evidence is being built. |
Instantly find 20 buyers from Virginia Tech
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with the Association for Molecular Pathology. Organization details are derived from AMP’s published lists. Submit a correction